Dr Olga Kubassova, CEO of IAG Joins Biotech Leaders In the British Parliament, House of Westminster
Dr. Olga Kubassova, CEO of Image Analysis Group (IAG), was distinguished as a guest of honor at the 6th Global Medical Excellence Awards Dinner and Ceremony, held in the House of Commons at the British Parliament, recognizing her for her influential role in advancing medical innovation in drug development.
The event, which took place on the 1st December 2023, celebrated exemplary contributions and leadership within the medical professionals, bringing together physicians, thought leaders, and investors.
Dr. Kubassova’s attendance as a guest of honor was at the invitation of the Tamil Society and Dr. Ajay Agrawal, Managing Director Europe at Ignite Capital Partners.
IAG, under Dr. Kubassova’s leadership, has been at the forefront of revolutionizing how medical images are analyzed and interpreted, playing a pivotal role in accelerating drug development. The company’s commitment to excellence and innovation has garnered attention globally, and Dr. Kubassova’s presence at the Global Medical Excellence Awards furthers IAG’s status as a key player in the drug development sector.
“I am deeply honored to have been invited to join the Global Medical Excellence Awards Dinner,” said Dr. Kubassova. “This is a testament to the hard work of our medical professionals and their dedication to the evolution of the healthcare landscape.”
The Global Medical Excellence Awards are renowned for acknowledging outstanding accomplishments in various fields related to healthcare, and Dr. Kubassova’s recognition underscores the significance of IAG’s contributions to the industry.
About IAG, Image Analysis Group
About IAG, Image Analysis Group: IAG, Image Analysis Group, is a global strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA, and capabilities in development strategies to support medical innovation. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin